1h Free Analyst Time
The duchenne muscular dystrophy (DMD) therapeutics market is forecasted to grow by USD 4.37 billion during 2023-2028, accelerating at a CAGR of 28.21% during the forecast period. The report on the duchenne muscular dystrophy (DMD) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high unmet need for duchenne muscular dystrophy therapeutics, increasing strategic alliances among the vendors, and introduction of patient assistance programs.
The duchenne muscular dystrophy (DMD) therapeutics market is segmented as below:
By Type
- Biologics
- Small molecules
By Distribution Channel
- Offline
- Online
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the duchenne muscular dystrophy (DMD) therapeutics market covers the following areas:
- Duchenne muscular dystrophy (DMD) therapeutics market sizing
- Duchenne muscular dystrophy (DMD) therapeutics market forecast
- Duchenne muscular dystrophy (DMD) therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global duchenne muscular dystrophy (dmd) therapeutics market: BioMarin Pharmaceutical Inc., Capricor Therapeutics Inc., CRISPR Therapeutics AG, CVS Health Corp., Daiichi Sankyo Co. Ltd., Editas Medicine Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., FibroGen Inc., Italfarmaco Holding SPA, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., PTC Therapeutics Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc., The Cleveland Clinic Foundation, Vertex Pharmaceuticals Inc., and Wave Life Sciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is strong pipeline for duchenne muscular dystrophy therapeutics."
According to the report, one of the major drivers for this market is the high unmet need for duchenne muscular dystrophy therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BioMarin Pharmaceutical Inc.
- Capricor Therapeutics Inc.
- CRISPR Therapeutics AG
- CVS Health Corp.
- Daiichi Sankyo Co. Ltd.
- Editas Medicine Inc.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- FibroGen Inc.
- Italfarmaco Holding SPA
- Nippon Shinyaku Co. Ltd.
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- PTC Therapeutics Inc.
- Santhera Pharmaceuticals Holding AG
- Sarepta Therapeutics Inc.
- The Cleveland Clinic Foundation
- Vertex Pharmaceuticals Inc.
- Wave Life Sciences Ltd.
